An extended 9-month clopidogrel monotherapy regimen was superior to dual antiplatelet therapy (DAPT) in reducing clinically relevant bleeding without increasing ischemic events among acute coronary syndrome (ACS) patients at both high bleeding and ischemic risks (bi-risk) who had already completed 9-12 months of DAPT after drug-eluting stent (DES) implantation, randomized controlled trial data suggest.